New combo attack on tough liver cancer
NCT ID NCT05488522
Summary
This early-stage study is testing a new combination treatment for advanced liver cancer that cannot be cured by surgery. It combines precise, high-dose radiation (SBRT) with two immunotherapy drugs (atezolizumab and bevacizumab) to see if the body's immune system can better fight the cancer. The main goal is to find a safe dose of this combination for future testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104-4283, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.